NEW YORK CITY, NY / ACCESS Newswire / January 30, 2026 / Pomerantz LLP is investigating claims on behalf of investors of Nutanix, Inc. ("Nutanix" or the "Company") (NASDAQ:NTNX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Nutanix and certain of its officers and/or directors […]
NEW YORK CITY, NY / ACCESS Newswire / January 30, 2026 / Pomerantz LLP is investigating claims on behalf of investors of Corcept Therapeutics Incorporated ("Corcept" or the "Company") (NASDAQ:CORT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Corcept and certain of its officers and/or
NEW YORK CITY, NY / ACCESS Newswire / January 30, 2026 / Pomerantz LLP is investigating claims on behalf of investors of Zenas BioPharma, Inc. ("Zenas" or the "Company") (NASDAQ:ZBIO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Zenas and certain of its officers and/or
NEW YORK CITY, NY / ACCESS Newswire / January 30, 2026 / Pomerantz LLP is investigating claims on behalf of investors of Oracle Corporation ("Oracle" or the "Company") (NYSE:ORCL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Oracle and certain of its officers and/or directors
NEW YORK CITY, NY / ACCESS Newswire / January 30, 2026 / Pomerantz LLP is investigating claims on behalf of investors of Atlassian Corporation ("Atlassian" or the "Company") (NASDAQ:TEAM). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Atlassian and certain of its officers and/or directors
NEW YORK CITY, NY / ACCESS Newswire / January 30, 2026 / Pomerantz LLP is investigating claims on behalf of investors of Aquestive Therapeutics, Inc. ("Aquestive" or the "Company") (NASDAQ:AQST). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Aquestive and certain of its officers and/or
NEW YORK CITY, NY / ACCESS Newswire / January 30, 2026 / Pomerantz LLP is investigating claims on behalf of investors of Atara Biotherapeutics, Inc. ("Atara" or the "Company") (NASDAQ:ATRA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Atara and certain of its officers and/or
NEW YORK CITY, NY / ACCESS Newswire / January 30, 2026 / Pomerantz LLP is investigating claims on behalf of investors of CVRx, Inc. ("CVRx" or the "Company") (NASDAQ:CVRX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether CVRx and certain of its officers and/or directors
Q4 2025 pre-tax and pre-provision income of $9.0 million, a NEW RECORD! Net income of $5.9 million ($1.37 per share). LAKEWOOD, CO / ACCESS Newswire / January 30, 2026 / Solera National Bancorp, Inc. (OTC:SLRK) ("Company"), the holding company for Solera National Bank ("Bank"), a business-focused bank located in the Denver metropolitan area, today reported
NEW YORK CITY, NY / ACCESS Newswire / January 30, 2026 / Pomerantz LLP is investigating claims on behalf of investors of Trip.com Group Limited ("Trip.com" or the "Company") (NASDAQ:TCOM). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Trip.com and certain of its officers and/or